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    Respiratory Syncytial Virus7RSVis one of the major pathogen which caused 
lower respiratory tract infection in infants and young children around the world, the 
infants before 2 years almost infected with RSV, 50% of them will reinfect. In the latest 
global disease mortality analysis, about 6.7% of children death while one to twelve 
months were caused by RSV infection. Furthermore, infection in the elderly population 
will cause serious illness and death cases. There is no safe and effective vaccine yet, 
the only licensed RSV-specific drug is neutralization monoclonal antibody palivizumab 
(Synagis), but because of its lack of affordable dose, high IMD and its high prices, 
palivizumab is currently only used to reduce high risk of infection in immunodeficiency 
and congenital heart disease children. 
    In the previous study, we obtained a high neutralizing antibody 5C4 against protein 
F, which is 50-100 times more active than palivizumab in vitro. In the prophylactic 
experiment in mouse model, 5C4 reduced RSV infection more effective compare to 
1129(palivizumab mouse antibody), it is potential to develop as a drug in the future, but 
the 5C4’s high neutralization is unique to RSV type A strain, the ability to neutralize B 
strain is poor. Because of its potential in the drug industry, we decided to optimize 5C4 
neutralization antibody properties. 
    In this study, the rapid design of the optimization of antibody properties was 
achieved by calculating the energy-based analysis and stability calculation of biology, 
then screened by cell experiments. Firstly, to establish a rapid mutant antibody 
screening system, we initially built 293F eukaryotic cell expression system, to achieve 
the efficient expression of mutant antibodies. Next, three neutralization 5C4 variants 
were selected from 34 candidate mutant antibodies by cell system9then tested in animal 
models. The results showed that the mutant antibodies were still maintained the same 
prophylactic efficacy compare to the original 5C4. Furthermore, we used predictive 
















dominant antibody neutralized with RSV B virus. 
    These results have important implications for antibody design because they reveal 
the potential of computational modeling to design antibodies with improved function. 
The computational experiments provided enrichment for variants with improved 
binding, leading to an efficient laboratory process. Computational biology also provides 
a new direction for antibody and protein function optimization. 
 

















αȟ͹ αȟ̷ 1ȟ̷ 
6HB six helix bundle 0Ѕτȧɔ 
a.a. amino acid ʏĵс 
Ab Antibody ǧn 
CTL cytotoxic lymphocyte ͪΔʆǆ T ʽƋͪΔ 
CO2 Carbon dioxide  ]ʎÊ̪ 
ddH2O doble distilled water  丙νʒ 
DMSO Dimethylsulfoxide ]˻ĵE̡ 
DNA Deoxyribonucleic Acid Οʎɪ͘ɪс 
ELISA Enzyme-Linked Immunosorbent Assays рΈ̃”ѩϪғ 
F fusion protein σúς̌ 
FBS Fetal Bovine Serum Β˟υˀ 
FDA Food and Drug Administration Ҍčèζˠ͐˱Ž 
FI-RSV 




G glycoprotein9attachment protein ͖ѩς̌ 
GAM-HRP 




GFP Green Fluorescent Protein ͶΩες̌ 
HAE human airway epithelial MĈ”七$̏ 
HPIV3 human parainfluenza virustype 3 M 3 İ¾ʮǑ̇ʆ 
HRP Hoseradish peroxidase ГɫЙʎÊˠр 
hRSV human respiratory syncytial virus M͓Ĉ”七úΔ̇ʆ 
IC50 Half maximal inhibitory Concentration Ñǥ¹ʱƣ 
IgG Immube Globulin G ̃˰ς̌ G 
















kD kilo Daltons Ï七ų҆ 
Kn Kanamycin ×万义͚ 
L large nucleoprotein RNA Ήúр 
LRI Lower Respiratory Infections %Ĉ”七Ǒɠ 
M matrix protein ĵϺς̌ 
mAb Monoclonal Antibody Ôѱǧn7Ôǧ 
mM mmol/l ʉȐųʅÐ 
N nucleoprotein ɪωľς̌ 
P phosphoprotein ̭ς̌ 
PBS Phosphate Buffered Saline ̭с̒ͷαʺ 
PCR polymerase chain reaction  Ήúр严ƪêơ 
RNA Ribonucleic Acid ɪ͘ɪс 
RNase Ribonuclease ɪ͘ɪср 
rpm Revolutions Per Minute ʅ°юЌȜ 
RSV respiratory syncytial virus Ĉ”七úΔ̇ʆ 
SDS-PAGE 
sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
Ή*˕与Ι¬Θ˼ʨ 
SH small hydrophobic protein ű́ʒς̌ 
wt wildtype ъ˸İ 
w/v mass/volume  Ϻыʱƣ 























Long ɨĊ Schinerder ɨi˺AĨͪΔĴȻnŚ°̱Ǖ˚̇ʆ͕Ŕ͊ȥ
乏̎Șɜ&qè&̽Š̎Ʊ、9r RSV ̎˸ˠÊŚĊ°Ŕ˸ˠŚǆϺ̠̾ĵ
ɌĤɾ&¼̘¸ 1981 ƚƹ¸ RSV RNA ̎ʰƟͮɜƛşǕѱý9̙̠̾
ǚО ɾʾ 
1.2 JIþGÛ²µ6Ç 
    Ĉ”七úΔ̇ʆ7RSVƀA΍̇ʆƀ7Genus Pneumovirus9΍̇ʆE̵
7Subfamily Pneumovirinae9¾͖ʺ̇ʆ̵7Family Paramyxoviridae̎Ô΋Ϸ



























ϋ 1-1 RSV-A 'U΍̇ʆE̵Ǖą̎ʏĵсƟ²Ɖƨ
	
Table 1-1 Amino acid sequence identify between the proteins of RSV subgroup A 
and the indicated members of subfamily Pneumovirinae 
Virus Compared 
Amino acid sequence identify for the indicated protein (%) 
NS1 NS2 N P M SH G F M2-1 M2-2 L 
RSV-A 
RSV-B 87 92 96 91 91 76 53 89 92 72 93 
BRSV 69 84 93 81 89 38 30 81 80 42 84 
PVM 16 20 60 33 42 23 12 43 43 10 53 
HMPV-A - - 42 35 38 23 15 33 36 17 45 
AMPV-A - - 41 32 38 19 16 35 37 12 43 
		-*	-	
1.3 JIþGÛ²µ²È\ 
    RSV ̇ʆ͕ŔȵЮЙŨ4ͪΔ$̎ΛϺΣÉϑÔ΋Ϸ严 RNA ƱǕ 7̎Ħ 1-
1 a,bJeffree ͊[10]ë˭9ЮЙͪΔĴI˸̎̇ʆɅ-̴Ʊ、9°¶ȵ̘Ƶ 100-
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